Insulin Use and Persistence in Type 2 Diabetes Patients
Author Information
Author(s): Bonafede Machaon M, Kalsekar Anupama, Pawaskar Manjiri, Ruiz Kimberly M, Torres Amelito M, Kelly Karen R, Curkendall Suellen M
Primary Institution: Thomson Reuters Inc
Hypothesis
What factors are associated with persistence to mealtime insulin among patients with type 2 diabetes on stable basal insulin therapy?
Conclusion
Mealtime insulin use and persistence were both considerably lower than expected, especially for human insulin compared to analogs.
Supporting Evidence
- Patients primarily used vial/syringe (87%) and insulin analogs (60%).
- Persistence to mealtime insulin was 40.7%, 30.2%, and 19.1% at 3, 6, and 12 months, respectively.
- Initiating mealtime insulin with human insulin was a risk factor for non-persistence.
- Older age, increased insulin copayment, mental health comorbidity, and polypharmacy were also predictors of non-persistence.
Takeaway
This study looked at how well patients with type 2 diabetes stick to their mealtime insulin after starting it, and found that many stop using it sooner than expected.
Methodology
A retrospective analysis using Thomson Reuters MarketScan® databases to assess insulin use and persistence among patients with type 2 diabetes.
Potential Biases
Potential for incomplete or miscoded claims impacting results.
Limitations
The study lacks data on lab values and physician behavior, which may affect the findings.
Participant Demographics
51% male, mean age 60.3 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website